MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease

Annals of Hepatology, Journal Year: 2024, Volume and Issue: 29(5), P. 101512 - 101512

Published: May 6, 2024

Fatty liver disease is a multisystem disease. Metabolic dysfunction-associated fatty (MAFLD) more accurate indicator of chronic kidney (CKD) than nonalcoholic (NAFLD). However, the relationship between recently defined metabolic steatotic (MASLD) and CKD currently unclear. The objective this cross-sectional study was to investigate prevalence albuminuria among individuals diagnosed with either MAFLD or MASLD.

Language: Английский

---

MAFLD identifies patients with significant hepatic fibrosis better than MASLD

Hepatology International, Journal Year: 2024, Volume and Issue: 18(3), P. 964 - 972

Published: May 8, 2024

Language: Английский

---

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

---

Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach

Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)

Published: Nov. 12, 2022

Abstract Background Nonalcoholic fatty liver disease is associated with an increased cardiovascular (CVD) risk, although the exact mechanism(s) are less clear. Moreover, relationship between newly redefined metabolic-associated (MAFLD) and CVD risk has been poorly investigated. Data-driven machine learning (ML) techniques may be beneficial in discovering most important factors for patients MAFLD. Methods In this observational study, MAFLD underwent subclinical atherosclerosis assessment blood biochemical analysis. Patients were split into two groups based on presence of (defined as at least one following: coronary artery disease; myocardial infarction; bypass grafting; stroke; carotid stenosis; lower extremities stenosis). The ML utilized to construct a model which could identify individuals highest CVD. We exploited multiple logistic regression classifier operating discriminative patient’s parameters selected by univariate feature ranking or extracted using principal component analysis (PCA). Receiver characteristic (ROC) curves area under ROC curve (AUC) calculated investigated classifiers, optimal cut-point values from Youden index, closest (0, 1) criteria Index Union methods. Results 191 (mean age: 58, SD: 12 years; 46% female), there 47 (25%) who had history clinical variables included hypercholesterolemia, plaque scores, duration diabetes. five, ten fifteen fit models resulted AUC 0.84 (95% confidence interval [CI]: 0.77–0.90, p < 0.0001), 0.86 CI 0.80–0.91, 0.0001) 0.87 0.82–0.92, whereas fitted over 10 components PCA followed parallel obtained 0.81–0.91, 0.0001). best 5 features correctly identified 114/144 (79.17%) low-risk 40/47 (85.11%) high-risk patients. Conclusion A approach demonstrated high performance identifying prevalent easy-to-obtain patient parameters.

Language: Английский

---

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care

Internal and Emergency Medicine, Journal Year: 2023, Volume and Issue: 18(4), P. 993 - 1006

Published: Feb. 17, 2023

Abstract The term non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common type of chronic disease. NAFLD points to excessive hepatic fat storage and no evidence secondary accumulation in patients with “no or little alcohol consumption”. Both etiology pathogenesis are largely unknown, a definitive therapy is lacking. Since very often closely associated metabolic dysfunctions, consensus process ongoing shift acronym MAFLD, i.e., metabolic-associated change terminology likely improve classification affected individuals, awareness, comprehension pathophysiological aspects involved, choice more personalized therapeutic approaches while avoiding intrinsic stigmatization due “non-alcoholic”. Even recently, other sub-classifications have been proposed concentrate heterogeneous causes under one umbrella. While awaiting additional validation studies this field, we discuss main reasons underlying important paradigm.

Language: Английский

---

Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease

Hepatoma Research, Journal Year: 2024, Volume and Issue: 10, P. 16 - 16

Published: Jan. 1, 2024

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic disease. This term does not describe pathogenetic mechanisms and complications associated with NAFLD. The new definition, Metabolic Dysfunction-associated Steatotic Liver (MASLD), emphasizes relationship between NAFLD cardiometabolic comorbidities. Cardiovascular features, such as arterial hypertension atherosclerosis, are frequently patients MASLD. Furthermore, these have a high risk developing neoplastic diseases, primarily hepatocellular carcinoma, but also extrahepatic tumors, esophageal, gastric, pancreatic cancers. Moreover, several studies showed correlation MASLD endocrine imbalance gut microbiota, systemic inflammation, obesity, insulin resistance play key role in development complications. narrative review aims to clarify evolution from nomenclature evaluate its

Language: Английский

---

Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)

Published: March 27, 2025

Fatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists other diseases, such alcohol-related and viral hepatitis, complicating both diagnosis management. To address the limitations of non-alcoholic fatty (NAFLD) classification, two alternative frameworks have been proposed: dysfunction-associated (MAFLD) in 2020 steatotic (MASLD) 2023. A key difference between these definitions is how they consider relation to coexistence conditions. MAFLD adopts dual etiology concept, creating unified classification system that aligns contemporary clinical epidemiological needs. In contrast, MASLD introduces new term, MetALD (metabolic alcohol-related/associated disease), describe patients who excessive alcohol intake. review critically examines clinical, research, implications differing approaches MASLD, offering insights into their potential enhance understanding management multi-etiology diseases.

Language: Английский

---

Metabolic dysfunction: The silenced connection with fatty liver disease

Annals of Hepatology, Journal Year: 2023, Volume and Issue: 28(6), P. 101138 - 101138

Published: July 18, 2023

Non-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, has not received sufficient attention compared to associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed rename NAFLD metabolic dysfunction-associated (MAFLD) order recognize risk factors complex pathophysiological mechanisms with development. Furthermore, along implementation of diagnostic criteria, aim is address whole clinical spectrum disease, regardless BMI presence other hepatic comorbidities. As would be expected paradigm shift, differing viewpoints have emerged regarding benefits disadvantages renaming disease. The following review aims describe way MAFLD from historical, perspective highlight why approach follow.

Language: Английский

---

An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: April 10, 2023

Abstract Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common cause of chronic and can progress to nonalcoholic steatohepatitis cirrhosis. This study aims summarize the evidence for effects curcumin on MAFLD progression. Studies were identified from Medline Scopus databases until April 2022. Systematic reviews meta-analyses (SRMA) randomized controlled trials (RCT) selected based pre-specified criteria. Three reviewers independently extracted data assessed quality included studies. Of 427 records, 6 SRMAs 16 RCTs in analysis. Very high overlap was observed among with corrected covered area 21.9%. From an updated meta-analysis, demonstrated significant improvement aspartate alanine aminotransferase pooled mean difference [95% confidence interval (CI)] −3.90 (−5.97, −1.82) −5.61 (−9.37, −1.85) units/L, respectively. Resolution hepatic steatosis higher than control group relative risk (95% CI) 3.53 (2.01, 6.22) 3.41 (1.36, 8.56), Curcumin supplementation also led lower fasting blood sugar, body mass index, total cholesterol. Further should be conducted assess effect histology, especially regarding non-invasive fibrosis steatosis.

Language: Английский

---

Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 80(5), P. e194 - e197

Published: Feb. 10, 2024

A multisociety Delphi consensus statement on new fatty liver disease nomenclatureJournal of HepatologyVol. 79Issue 6PreviewThe principal limitations the terms NAFLD and NASH are reliance exclusionary confounder use potentially stigmatising language. This study set out to determine if content experts patient advocates were in favour a change nomenclature and/or definition. modified process was led by three large pan-national associations. The defined priori as supermajority (67%) vote. An independent committee external made final recommendation acronym its diagnostic criteria. Full-Text PDF Open Access In tremendous conceptual advance, Eslam et al.1Eslam M. Newsome P.N. Sarin S.K. al.A definition for metabolic dysfunction-associated disease: an international expert statement.J Hepatol. 2020; 73: 202-209Abstract Full Text PubMed Scopus (2259) Google Scholar, 2Eslam Sanyal A.J. George J. al.MAFLD: consensus-driven proposed associated disease.Gastroenterology. 158: 1999-2014. e1Abstract (1854) 3Eslam Alkhouri N. Vajro P. al.Defining paediatric (dysfunction)-associated statement.Lancet Gastroenterol 2021; 6: 864-873Abstract (126) Scholar put forth two landmark articles that changed narrative with dysfunction, including correction from non-alcoholic (NAFLD) (MAFLD) more apt term. They also introduced simple appropriate "positive" criteria diagnosing disease, alcohol intake or other diseases. These apply both adults children is continuum across lifespan. We among societies stakeholders endorsed this proposal multitude reasons,4Shiha G. Alswat K. Al Khatry al.Nomenclature metabolic-associated Middle East north Africa.Lancet 57-64Abstract (111) 5Spearman C.W. Desalegn H. Ocama al.The sub-Saharan Africa position redefinition MAFLD.J 74: 1256-1258Abstract (37) 6Méndez-Sánchez Bugianesi E. Gish R.G. al.Global multi-stakeholder endorsement MAFLD definition.Lancet 2022; 7: 388-390Abstract (147) a) value evidence: wealth data have provided unequivocal evidence superior utility compared traditional various outcomes.7Alharthi Gastaldelli A. Cua I.H. Ghazinian Metabolic year review.Curr Opin Gastroenterol. 38: 251-260Crossref (38) b) simplicity practicality these c) Nomenclature devoid any stigma appropriately reflects pathophysiology makes it easier communicate patients, general practitioners, nurses, non-hepatology specialists policy makers.8Shiha Korenjak Eskridge W. al.Redefining perspective.Lancet 73-79Abstract (131) 9Clayton Fabrellas Luo al.From MAFLD: nurse allied health perspective.Liver Int. 41: 683-691Crossref (34) 10Farahat T.M. Ungan Vilaseca paradigm shift global primary care viewpoint.Liver 42: 1259-1267Crossref (14) 11Eslam Ahmed Després J.-P. al.Incorporating multidisciplinary novel clinical trial designs patients diseases.Lancet 743-753Abstract (56) Recently after lengthy complex raised questions than resolved, attempt develop another disease. group under umbrella using term steatotic disease" (MASLD) adopted MAFLD.12Rinella M.E. Lazarus J.V. Ratziu V. multi-society nomenclature.Ann 2023; 101133PubMed As regional leaders, whose utmost priority our we spent several months analysing views stance it. Consequently, African Association Gastroenterology (AMAGE), we, undersigned, comprising over 100 signatories representing multiple key opinion leaders 31 countries, decided continue name overarching diseases dysregulation official terminology region. decision based on: 1) Emerging suggesting accurately underlying pathogenesis better at identifying those high risk outcomes MASLD At minimum, did not lead significant improvements can justify confusion could be caused change.13Chen L. Tao X. Zeng Mi Y. Xu Clinical histological features different nomenclatures NAFLD, MAFLD, MetALD.J Scholar,14Zhao Q. Deng Comparison mortality individuals Abstract (7) Additionally, numerous studies demonstrated lack granularity specificity15Tanaka Mori Takahashi S. al.Metabolic dysfunction–associated predicts onset chronic kidney nonalcoholic disease.Nephrol Dial Transplant. 700-711Crossref (20) Scholar,16Anirvan Khatua C.R. Panigrahi M.K. Singh S.P. Definition dysfunction: shifting goalposts.J Clin Exp Scholar. Therefore, only one maintains right balance between sensitivity specificity. finding expected implications cost-effective analysis. 2) argument "fatty" stigmatising. However, statements refuted claim. point has been illustrated patients' spokespeople, who highlighted "in some cultures being fat regarded sign good health".17Shiha Casanovas T. al.MAFLD 2022: ELPA/ALPA/EASO-ECPO joint stigma.J 77: 1717-1719Abstract (12) recent showed perception varies significantly providers, geographic locations, sub-specialties. Only 8% perceived 38% doctors.18Younossi Z.M. AlQahtani S.A. survey physicians disease.J Another necessarily all cultures.19Méndez-Sánchez Pal S.C. Fassio Díaz-Ferrer Prado-Robles J.A. stigma—a single-center Mexican survey.Hepatol 17: 507-508Crossref (6) "steatotic" same translation languages spoken believe findings collectively weaken changing "steatotic". sufficient basis avoid abrupt changes Studies shown transition positive increasing awareness healthcare providers. It increases attention conferences countries systems.20Fouad Gomaa Semida Ghany W.A. Attia D. Change specialists.J 1254-1256Abstract (51) Scholar,21Fouad Abdel Salam AbdAllah expands information flow.Hepatol Res. 52: 488-489Crossref (2) conclusion, considering North Africa, well Sub-Saharan endorse instead opted existing before. Asian Pacific Study Liver (APASL) taken decision. Further confirm validity needed. No funding obtained required study. All authors nothing disclose relevant work. Please refer accompanying ICMJE disclosure forms further details. shared conceptualisation designed idea. Yasser Fouad wrote initial draft. revised manuscript approved version. contributing list: Sherief M Abd-elsalam Tropical Medicine Infectious Diseases Department, Faculty Medicine, Tanta University, Tanta, Egypt. Mohamed Department Gastroenterology, Hepatology, Medical Research Division, National Center, Nermeen Abdeen Alexandria Alexandria. Shereen Abdelaleem Endemic Cairo Cairo, Abdelghani Hepatology Minia Minia, Wafaa Abdelhamid Haitham Hamid Nadia Abdelaaty Ain Shams Mostafa Abdellhalim Ministry Health population, Abdelmohsen Assiut Assiut, Doaa Abdeltawab Mosaab Abdulkarim Tripoli medical university, Libya. Bounena Abidine Centre Hospitalier de Nouakchott, Mauritania. Aboalela YousryAboamer Mahala Teaching Hospital, Sayed Mohammed Amer Internal Al-Azhar Kafya Akrouf Al-Amiri Kuwait City, Kuwait. Hameed Jameel university Kerbala, Iraq. Munira Tarrah Abeer Al-Gharabally Nourhan Alaa Ataa Pezhman Alavinejad School Alimentary Tract Imam Khomeini Ahvaz Jundishapur University Sciences, Khuzestan, Iran. Moussa Ali Mahamat Chad. Alice Guingané Département d'Hépato-gastroentérologie, Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso. Taha Alkarboly Kurdistan Center Assulaymaniah, Kurdistan, Nawal Alkhalidi & Environment, Baghdad, Abdullah Alyouzbaki College Mosul, Nazugum Ashimova Astana Astana, Kazakhstan. Badi Hamad corporation, Qatar. Ibrahim Halil Bahcecioglu Firat Turkey. Shamardan Bazeed South Valley Qena, Asad Dajani ADSC, Medcare Hospital Saudi German Sharjah, Khan, PO Box 6328, United Arab Emirates. Mahmoud Desoky Division Sultan bin Abdulalaziz city, Arabia. Ibrahima Diallo Hepatogastroenterology, Hôpital Principal Dakar, Senegal. Elbadri Corporation, Amr Elsayed tropical medicine department, Aisha Elsharkawy Elwazzan Alexandria, Eman Fares Fayoum Manar Farhat Yasmine Gaber Manik Gemilyan Yerevan State Armenia. Yahya Ghanem Sanaa college, Yemen. Fayoum, Gueye Président Saafara Hépatites, Sénégal. Azaa Hafez Nursing, Gagik Hakobyan Adel Hasan Suez Canal Suez, Fuad Royale Hayat Alshymaa Hassnine Hassanin Bilal Hotayt Khoury Hamra, Beirut, Lebanon. Alkassoum Salifou Abdou Moumouni Niamey, Niger. Enas Kamal Qalandar Kasnazan Higher Council Fir Specialities, KHCMS, Rofida Khalifa Ashkhen Keryan Nikomed center, Khan King Abdulla Mecca, Saro Khemichyan Gastrointestinal Diseases, Keck USC, Elmira Kuantay S.D. Asfendiyarov Kazakh Liver, Almaty, Dlovan Khoushnow DK radiology clinic, Erbil Governorate, Reem Mahdy Assuit Amna Saltanat Madenova Gayane Matsakyan Nahed Makhlouf Assuit, Mai Mehrez Armed Forces Souraia Mezhoud corporation HMC, Eileen Micah Komfo Anokye Kumasi, Ghana. Safaa Abdelhalim Menna centre, Shaymaa Nafady Beni-Suef Beni Suef, Aren Nersisyan Alexander Nersesov Kalys Nogoibaeva Kyrgyz Academi, Kyrgyzstan. Necati ORMECİ İstanbul Technology Istanbul, Türkiye. Marian Muse Osman Somalia Institute Health, Somalia. Venera Rakhmetova Abdulfattah Rajab department Central Aigul Raissova Ebada Said Benha Benha, Asmaa Salama Ruzanna Safaryan Violeta Sargsyan Nady Semeda Nara Stepanyan Isaac Thom Shawa Malawi Blantyre, Malawi. Aya Shazly health, Taharboucht CHU Douera, Blida, Algiers, Algeria. Tumi Liya, Mariam Zaghloul Kafrelsheikh University,Egypt. Samy Zaky Hepatogastroenterology following supplementary article: Download .pdf (.95 MB) Help pdf files Multimedia component 1

Language: Английский

---